Conversion Labs Announces PDF Simpli Achieves Milestone of Over 1 Million Registered Users
Download as PDF
May 01, 2019
NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (CVLB) (“Conversion Labs” or “Company”), an e-commerce company focused on building and scaling innovative branded consumer products, today announced that the Company’s majority owned subsidiary, LegalSimpli Software LLC, achieved a milestone of over 1 million registered users of its PDF Simpli software product.
PDF Simpli, accessible at www.pdfsimpli.com, is a software as a service product that allows users to easily edit, convert, compress, split, or compress PDF files. Conversion Labs acquired 51% of Legal Simpli Software LLC in June of 2018. Since its investment, PDF Simpli has grown from approximately 10,000 registrants to more than 1 million. PDF Simpli is presently ranked in the top 50,000 websites globally and is marketed in more than 100 countries around the world.
"The phenomenal growth of registered and subscribed users within our first year shows the size of the PDF market and that it is ripe for disruption. I cannot be more pleased with the performance year to date and see significant growth and revenue potential for the remainder of 2019 and beyond," stated Sean Fitzpatrick, CEO & President of LegalSimpli Software LLC. "This first Software as a Service business from Conversion Labs continues to complement the extensive physical product offerings, while increasing margin growth into the future.”
About Conversion Labs
Conversion Labs, Inc. (the "Company") is an e-commerce company with a portfolio of innovative and proprietary brands. Conversion Labs’ scalable and global advertising technology infrastructure leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.conversionlabs.com or email us at firstname.lastname@example.org.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause Conversion Labs, Inc.’s actual results to differ materially from those anticipated by the forward-looking statements. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC.
Source: Conversion Labs, Inc.
Released May 1, 2019